"HIV Protease Inhibitors" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Inhibitors of HIV PROTEASE, an enzyme required for production of proteins needed for viral assembly.
| Descriptor ID |
D017320
|
| MeSH Number(s) |
D27.505.519.389.745.420 D27.505.954.122.388.077.088.420
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "HIV Protease Inhibitors".
Below are MeSH descriptors whose meaning is more specific than "HIV Protease Inhibitors".
This graph shows the total number of publications written about "HIV Protease Inhibitors" by people in this website by year, and whether "HIV Protease Inhibitors" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2000 | 0 | 1 | 1 |
| 2003 | 1 | 1 | 2 |
| 2004 | 2 | 0 | 2 |
| 2006 | 2 | 1 | 3 |
| 2007 | 0 | 1 | 1 |
| 2008 | 2 | 0 | 2 |
| 2009 | 1 | 1 | 2 |
| 2010 | 2 | 1 | 3 |
| 2011 | 3 | 0 | 3 |
| 2012 | 1 | 0 | 1 |
| 2013 | 1 | 1 | 2 |
| 2014 | 2 | 2 | 4 |
| 2015 | 4 | 1 | 5 |
| 2016 | 4 | 2 | 6 |
| 2018 | 3 | 0 | 3 |
| 2019 | 5 | 0 | 5 |
| 2020 | 2 | 0 | 2 |
| 2021 | 1 | 1 | 2 |
| 2022 | 1 | 0 | 1 |
| 2024 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "HIV Protease Inhibitors" by people in Profiles.
-
Safety and Pharmacokinetics of Lopinavir/Ritonavir Oral Solution in Preterm and Term Infants Starting Before 3 Months of Age. Pediatr Infect Dis J. 2024 Apr 01; 43(4):355-360.
-
Third-line antiretroviral therapy, including raltegravir (RAL), darunavir (DRV/r) and/or etravirine (ETR), is well tolerated and achieves durable virologic suppression over 144 weeks in resource-limited settings: ACTG A5288 strategy trial. J Int AIDS Soc. 2022 06; 25(6):e25905.
-
Dolutegravir as First- or Second-Line Treatment for HIV-1 Infection in Children. N Engl J Med. 2021 12 30; 385(27):2531-2543.
-
Safety and Pharmacokinetics of Double-Dose Lopinavir/Ritonavir + Rifampin Versus Lopinavir/Ritonavir + Daily Rifabutin for Treatment of Human Immunodeficiency Virus-Tuberculosis Coinfection. Clin Infect Dis. 2021 08 16; 73(4):706-715.
-
The dual protease inhibitor lopinavir/ritonavir (LPV/r) exerts genotoxic stress on lung cells. Biomed Pharmacother. 2020 Dec; 132:110829.
-
Drug level testing as a strategy to determine eligibility for drug resistance testing after failure of ART: a retrospective analysis of South African adult patients on second-line ART. J Int AIDS Soc. 2020 06; 23(6):e25501.
-
Descriptive analysis of World Health Organization-recommended second-line antiretroviral treatment: A retrospective cohort data analysis. S Afr Med J. 2019 Nov 27; 109(12):919-926.
-
Third-line antiretroviral therapy in low-income and middle-income countries (ACTG A5288): a prospective strategy study. Lancet HIV. 2019 09; 6(9):e588-e600.
-
Low Frequency of Protease Inhibitor Resistance Mutations and Insertions in HIV-1 Subtype C Protease Inhibitor-Naïve Sequences. AIDS Res Hum Retroviruses. 2019 07; 35(7):673-678.
-
Growth in HIV-1-exposed but uninfected infants treated with lopinavir-ritonavir versus lamivudine: a secondary analysis of the ANRS 12174 trial. Lancet HIV. 2019 05; 6(5):e307-e314.